Invesco Dorsey Wright Healthcare Momentum ETF PTH
59.35 USD -0.56 (-0.94%)
At closeNov 10, 2026, 4:00 PM EST
59.35 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
58.81 Day range 59.98
46.09 52-week range 64.10
- YTD
- +19.42%
- 1 year
- +23.88%
News
globenewswire.com TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney…
globenewswire.com Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5…
zacks.com Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)? If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), a passively managed…
gurufocus.com Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026 HONG KONG, Aug 31, 2026 - (ACN Newswire) - Operating Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital StructureOn August 2
benzinga.com Moderna Advances Ebola Vaccine Into Human Testing Moderna starts Phase 1 trials for Ebola vaccine mRNA-1469. See premarket MRNA stock reaction, analyst updates, and ETF exposure.
globenewswire.com Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase…
zacks.com Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)? If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), a passively managed…
globenewswire.com Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected…
globenewswire.com Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with…
globenewswire.com 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism – Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment…
businesswire.com Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today…
globenewswire.com Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its…
globenewswire.com Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers
benzinga.com Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
globenewswire.com OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities
globenewswire.com OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that s uccessfully combine s Entera's oral peptide N- Tab ® platform with OPKO 's advanced protein chemistry capabilities
benzinga.com FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted treatment.
globenewswire.com Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections Novel PTH analog achieves…
globenewswire.com New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal…
globenewswire.com 3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of…
benzinga.com Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.
globenewswire.com New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with…
benzinga.com US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21.
benzinga.com FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen' FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency.
benzinga.com Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst Needham analyst initiates coverage on Hims & Hers Health, Inc. with a Buy rating and $24 price target. Anticipates positive impact from GLP-1 market entry and strong growth potential.
benzinga.com 3 Health Care ETFs Where Components Are Enduring Downgrades After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.- benzinga.com Investors Are Flocking To This New ETF
benzinga.com Riding The ETF Momentum Into 2016 
benzinga.com The Final Four: New ETF Focuses On Four Momentum Funds - benzinga.com Two Sub-$100M ETFs That Have Outperformed Larger Rivals
benzinga.com Analogic Earnings Preview: EPS Expected to Double - benzinga.com Twelve Health Care ETFs Trading Near 52-Week Highs